Last C$0.76 CAD
Change Today -0.02 / -2.56%
Volume 239.6K
IMV On Other Exchanges
Symbol
Exchange
Venture
OTC US
Frankfurt
As of 10:48 AM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

immunovaccine inc (IMV) Snapshot

Open
C$0.78
Previous Close
C$0.78
Day High
C$0.78
Day Low
C$0.75
52 Week High
02/7/14 - C$1.50
52 Week Low
12/18/13 - C$0.35
Market Cap
69.5M
Average Volume 10 Days
264.7K
EPS TTM
--
Shares Outstanding
91.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMMUNOVACCINE INC (IMV)

Related News

No related news articles were found.

immunovaccine inc (IMV) Related Businessweek News

No Related Businessweek News Found

immunovaccine inc (IMV) Details

Immunovaccine Inc., a clinical-stage biopharmaceutical company, discovers and develops activators of the immune system to treat cancer and prevent infectious diseases. The company develops its products based on DepoVax vaccine-adjuvanting platform, a vaccine delivery formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system. Its product candidates include DPX-Survivac, a therapeutic cancer vaccine, which has completed Phase I clinical trials for the treatment of ovarian and brain cancer; and DPX-0907, a therapeutic cancer vaccine that has completed Phase I clinical trials for the treatment of breast, ovarian, and prostate cancer. The company also develops pre-clinical stage vaccine product candidates for infectious diseases, including respiratory syncytial virus and anthrax. In addition, its product pipeline consists of DepoVax-validating partnered programs for addiction medicine and animal health. Immunovaccine Inc. was founded in 2000 and is headquartered in Halifax, Canada.

21 Employees
Last Reported Date: 08/14/14
Founded in 2000

immunovaccine inc (IMV) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: C$200.0K
Chief Financial Officer and Corporate Secreta...
Total Annual Compensation: C$128.8K
Compensation as of Fiscal Year 2013.

immunovaccine inc (IMV) Key Developments

Immunovaccine Inc. Announces Positive Results from Anthrax Challenge Studies

Immunovaccine Inc. announced positive results from anthrax challenge studies in non-human primates (monkeys) using an anthrax vaccine formulated with Immunovaccine's DepoVax(TM) delivery system. The studies, performed by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), showed that subjects given a single dose of the DepoVax(TM) -based vaccine were protected against a lethal anthrax challenge. The DepoVax(TM) formulated anthrax vaccine was tested as a single dose in monkeys to determine how quickly neutralizing antibodies can be produced by the vaccine and to test its ability to protect against a lethal dose of the anthrax causing bacterial spores (B. anthracis). A group of six animals vaccinated with a single dose of the vaccine was protected from anthrax infection. Four of the five animals in the study's positive control group receiving BioThrax(R) were protected as well; however, they were given two doses of the control vaccine. BioThrax(R) is the only FDA-licensed vaccine however multiple immunizations are needed to provide the necessary protection against exposure to anthrax. Three doses of intramuscular injections of BioThrax(R) are indicated at 0, 1, and 6 months, followed by booster injections at 12 and 18 months. There is currently no licensed anthrax vaccine that can provide protection with one dose. In all animals immunized with the DepoVax(TM) -based vaccine, antibody titers generally peaked in the first 28 days then persisted until at least day 70, when animals were exposed to the disease agent. In contrast, animals in the control group receiving BioThrax(R) required a second dose to produce protective neutralizing titers.

ImmunoVaccine Inc. Announces Plans for Phase II Clinical Trial of DPX-Survivac in Patients with Recurrent Lymphoma

ImmunoVaccine Inc. provided a clinical development program update for DPX-Survivac. The Company plans to advance DPX-Survivac into a Phase II clinical study in diffuse large B cell lymphoma (DLBCL) later this year. The trial will evaluate DPX-Survivac in combination with oral cyclophosphamide, an immune modulating agent, in patients with recurrent DLBCL. This combination therapy trial design fits with Immunovaccine's clinical development strategy of maximizing therapeutic impact through concurrent treatment with various classes of promising immunotherapies. The efficacy Phase II trial will launch at the Odette-Sunnybrook Cancer Centre with the expectation of adding additional sites in the coming months. Researchers will seek to enroll up to 24 patients, with the first patient expected to be dosed by early 2015. The open label study is designed to determine the objective response rate of patients with recurrent survivin-expressing DLBCL when treated with DPX-Survivac in combination with low dose oral cyclophosphamide. Immunovaccine expects to have initial clinical data from this study available approximately mid 2015. Positive clinical data from this study could provide rationale for the initiation of a pivotal trial in recurrent DLBCL. Lymphoma is a relevant oncologic target for DPX-Survivac as more than half of all aggressive non-Hodgkin's lymphomas such as DLCBL express survivin, the tumor-associated antigen that serves as the basis for the vaccine. Furthermore, there is a growing body of clinical research that shows activity for immune modulatory agents such as cyclophopsphamide in DLCBL. Importantly, lymphoma represents a significant unmet medical need as patients who are not transplant candidates or who experience recurrence following an autologous stem cell transplant (ASCT) lack additional treatment options.

ImmunoVaccine Inc. Announces Board Changes

ImmunoVaccine Inc. has elected Wade K. Dawe and Alfred A. Smithers to its board of directors. The appointments are effective immediately. Mr. Dawe is a successful entrepreneur and financier credited with raising more than $400 million for both private and public companies during the course of his career. He most recently served as Chairman and Chief Executive Officer of Brigus Gold Corp. Currently the President and Chief Executive Officer of Iona Resources Holdings Limited, Mr. Smithers was founder and former President and Chief Executive Officer of the Secunda Group of Companies. Mr. Smithers currently sits on the board of directors of the Dartmouth General Hospital. The company also announced that Stephanie Léouzon and Llew Keltner are stepping down from their positions on the board. Dr. Keltner will continue to serve as a consultant to the company in the area of business development.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMV:CN C$0.76 CAD -0.02

IMV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMV.
View Industry Companies
 

Industry Analysis

IMV

Industry Average

Valuation IMV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 622.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOVACCINE INC, please visit www.imvaccine.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.